The evolving clinical management of cerebral metastases

Eur J Surg Oncol. 2017 Jul;43(7):1173-1185. doi: 10.1016/j.ejso.2016.10.006. Epub 2016 Oct 27.

Abstract

Concepts in the management of brain metastases are evolving. Until recently, brain metastases have been considered as a homogenous condition, managed with whole brain radiotherapy, surgical resection for large lesions and stereotactic radiosurgery for smaller lesions. Increasingly, specific systemic medical therapies are being used to treat brain metastases based on the primary site of disease. This disease specific management is causing a change in perspective about brain metastases and has led to improved survival for patients with primary disease subtypes amenable to tailored medical therapies. We review the recent literature to present evidence for the use of subtype specific medical therapies, advances in surgical resection techniques and stereotactic radiosurgery as the primary treatment modalities. The decline in use of whole brain radiotherapy as first line treatment is also discussed. Based on the recent literature, we propose a new management algorithm to reflect the progress in available options for tailoring disease specific treatments and support the change in paradigm to consider brain metastases as separate disease states based on the primary site of cancer rather than as a homogenous entity.

Keywords: Cerebral metastases; Chemotherapy; Neurosurgery; Radiotherapy; Stereotactic radiosurgery.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / complications
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / therapy*
  • Breast Neoplasms / pathology*
  • Humans
  • Lung Neoplasms / pathology*
  • Melanoma / secondary*
  • Neurosurgery
  • Radiotherapy / methods
  • Urogenital Neoplasms / pathology*

Substances

  • Antineoplastic Agents